Rapid & Powerful Efficacy in Head and Neck Areas29
Results of a Phase 4, open-label study of VTAMA cream in adults with mild to severe plaque psoriasis in the head and neck areas.29
Clearer skin in head and neck areas29
Robust efficacy demonstrated in treatment of adult patients with plaque psoriasis in the head and neck areas
88.5% of adult patients (n=26) achieved tPGA=0 (clear) or 1 (almost clear) and ≥2-grade improvement from baseline at week 1229
96.2% of adult patients (n=26) achieved PASI75 and 84.6% achieved PASI90 at week 1229
70% of adult patients with plaque psoriasis achieved itch relief
With ≥4-point improvement in PP-NRS at week 12 in Head and Neck Areas*30
*Patients with baseline PP-NRS score of ≥4 who achieved ≥4-point improvement in the PP-NRS.
PP-NRS is a Patient Reported Outcome.
Safe and well tolerated in head and neck areas30
Head and Neck Phase 4, Open-Label Safety Profile2,30,31
- VTAMA cream was well tolerated with no new safety signals.30
- The most common adverse reactions (incidence ≥ 5%) in subjects treated with VTAMA cream were folliculitis, contact dermatitis, headache, sinusitis, and seborrheic keratosis. In the two Phase 3 pivotal trials, the most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.2,31
- Three patients discontinued this Phase 4 study due to adverse events (contact dermatitis [n=2], headache [n=1]).31
Before and After Images
See the significant results from some adult patients using VTAMA cream in this Head & Neck plaque psoriasis Phase 4, open-label study. VTAMA cream helped adult patients with mild, moderate, and severe plaque psoriasis achieve clearer skin. Please note that the photographs you will see are representative of one target lesion on individual patients treated with VTAMA cream during this study.
Scalp 1
Age: 75 Gender: Female Patient: 1007-002
Primary Endpoint Success*30,31
Baseline
Physicians Rated‡
tPGA=3
Patient Rated§
DLQI=24
PP-NRS=10
PP-NRS=10
Week 1†
Physicians Rated‡
tPGA=2
Patient Rated§
DLQI=10
PP-NRS=7
PP-NRS=7
Week 12
Physicians Rated‡
tPGA=0
Patient Rated§
DLQI=0
PP-NRS=0
PP-NRS=0
Age: 70 Gender: Male Patient: 1003-004
Primary Endpoint Failure*31
Baseline
Physicians Rated‡
tPGA=3
Patient Rated§
DLQI=0
PP-NRS=1
PP-NRS=1
Week 4†
Physicians Rated‡
tPGA=0
Patient Rated§
DLQI=2
PP-NRS=2
PP-NRS=2
Week 12
Physicians Rated‡
tPGA=2
Patient Rated§
DLQI=4
PP-NRS=3
PP-NRS=3
Age: 55 Gender: Female Patient: 1003-001
Primary Endpoint Failure*31
Baseline
Physicians Rated‡
tPGA=2
Patient Rated§
DLQI=8
PP-NRS=5
PP-NRS=5
Week 1†
Physicians Rated‡
tPGA=1
Patient Rated§
DLQI=5
PP-NRS=2
PP-NRS=2
Week 12
Physicians Rated‡
tPGA=1
Patient Rated§
DLQI=1
PP-NRS=0
PP-NRS=0
Age: 24 Gender: Male Patient: 1006-002
Primary Endpoint Success*29,31
Baseline
Physicians Rated‡
tPGA=3
Patient Rated§
DLQI=5
PP-NRS=5
PP-NRS=5
Week 4†
Physicians Rated‡
tPGA=2
Patient Rated§
DLQI=0
PP-NRS=1
PP-NRS=1
Week 12
Physicians Rated‡
tPGA=1
Patient Rated§
DLQI=0
PP-NRS=0
PP-NRS=0
Age: 65 Gender: Female Patient: 1005-006
Primary Endpoint Success*31
Baseline
Physicians Rated‡
tPGA=3
Patient Rated§
DLQI=9
PP-NRS=7
PP-NRS=7
Week 2†
Physicians Rated‡
tPGA=2
Patient Rated§
DLQI=5
PP-NRS=6
PP-NRS=6
Week 12
Physicians Rated‡
tPGA=0
Patient Rated§
DLQI=2
PP-NRS=2
PP-NRS=2
*Primary endpoint success refers to the primary study endpoint of a patient achieving a tPGA score of 0 or 1 and ≥2-grade improvement from baseline at week 12.29
†Patient photos depict a single plaque psoriasis lesion in the head or neck region at baseline, visit with earliest visible improvement, and at week 12.29
‡The tPGA is a physician global assessment of a target lesion identified at baseline affecting the head and neck region. Example of 1 representative target lesion of a VTAMA cream-treated patient from clinical study. Individual results may vary.29
§DLQI and PP-NRS are Patient-Reported Outcomes.
Strictly Necessary Cookies
Previous
